This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the optimal use of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and related diseases, including smouldering myeloma and solitary plasmacytoma.
Results of a meta-regression analysis have shown that, contrary to popular opinion, there is no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and survival in newly diagnosed myeloma patients. Published recently in the European Journal of Haematology, the researchers explored the relationship between response to initial…
DetailsMyeloma UK together with the British Committee for Standards in Haematology (BCSH) and the United Kingdom Myeloma Forum (UKMF) have jointly published new guidelines for the screening and management of the late and long-term consequences of myeloma and its treatments. Published recently in the British Journal of Haematology, the guidelines highlight the key late effects…
DetailsA study published recently in the Journal of the American Medical Association has found that administering zoledronic acid every 12 weeks instead of the current standard of every four weeks over two years, does not increase the risk of skeletal-related events (SREs) in patients with bone complications due to breast cancer, prostate cancer or myeloma.…
DetailsThese guidelines, produced by the British Society of Haematology (BSH) and the UK Myeloma Forum (UKMF), highlight the late and long-term effects of myeloma and its treatments, and summarise the national consensus for the screening and management of these effects.
Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. Chakraborty R et al. Blood Cancer J. 2016 Dec 16;6(12):e512. doi: 10.1038/bcj.2016.117. A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival. Botta C et al. Blood Cancer J. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118. 68Ga-PSMA PET/CT Imaging in Multiple Myeloma. Sasikumar A et…
DetailsResults from the national Myeloma XI trial have shown a higher incidence of second primary malignancies (SPM) in patients receiving Revlimid (lenalidomide) maintenance treatment compared to those who did not, in line with other previous reported trials. Published in the Blood Cancer Journal analysis of the data showed that, although the overall incidence of SPM was…
DetailsCelgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences (UAMS) have announced that they have partnered to create the Myeloma Genome Project to compile high quality genetic and clinical data to improve diagnosis, prognosis and treatment for myeloma patients. The aim is to develop a strategy for classifying myeloma into subgroups…
DetailsImproved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm. Horger M et al. Eur Radiol. 2016 Nov 23. [Epub ahead of print]. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Sawyer JR et al. Leukemia. 2016 Nov 4. doi: 10.1038/leu.2016.253. [Epub ahead of print]. Predictors of inferior clinical outcome in patients with…
Details